Patient explainer · Learn
Is stem cell therapy FDA-approved?
A direct answer to one of the most common questions patients ask about regenerative medicine, including the regulatory terms that clinic marketing often blurs.
Direct answer
No, with one important exception. The FDA has approved certain hematopoietic stem cell transplants and a small number of engineered cell and gene therapy products for specific blood, immune, and inherited disorders. It has not approved any stem cell or cellular therapy for the kinds of conditions most patients are searching about, orthopedic injury, post-COVID conditions, post-traumatic neurological symptoms, or chronic systemic disease.
01 · The distinction
What "FDA-approved" actually means.
The FDA regulates products it considers drugs or biologics: substances administered to patients to treat disease. To be FDA-approved, a product has to go through a defined sequence: preclinical testing, an Investigational New Drug (IND) application, three phases of clinical trials, and a Biologics License Application (BLA) or New Drug Application (NDA). Approval is product-by-product and indication-by-indication.
"Approved" is different from "available," "regulated," or "legal to administer." A clinical procedure performed in a doctor's office, a same-day, autologous tissue handling, can be legal medicine without any specific product being "FDA-approved." The FDA's regulatory authority kicks in when a cellular product crosses into drug territory: when it's more than minimally manipulated, when it's used non-homologously, when it's expanded in culture, when it's combined with another article, or when it comes from a donor.
That framework, the Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/P) framework, codified at 21 CFR 1271, is what determines whether a clinic's offering requires FDA pre-market approval or operates as a clinical procedure.1
Plain-language summary
"FDA-approved" means a specific product, for a specific indication, has been through the drug-approval process. The FDA does not approve clinics, procedures, or whole categories of treatment.
02 · What is approved
A small, important set of cellular products has full FDA approval.
The FDA's Center for Biologics Evaluation and Research (CBER) maintains a current list of approved cellular and gene therapy products.2 The major categories:
Hematopoietic stem cell transplants. Bone marrow and umbilical-cord blood transplants for certain leukemias, lymphomas, severe aplastic anemia, and inherited immunodeficiencies. Standard of care for decades. Represents the vast majority of "stem cell therapy" performed in the U.S., and is profoundly different from what most regenerative-medicine clinics offer.
FDA maintains a list of approved cord blood products for specific hematopoietic indications. Used in transplant medicine, not in regenerative or orthopedic contexts.
A growing group of products, including Yescarta, Kymriah, and Breyanzi, made by engineering a patient's own immune cells in a lab to attack certain blood cancers. Related gene-modified cell therapies are approved for some inherited blood disorders. These are manufactured, gene-engineered cell products, not the autologous bone marrow concentrates patients typically encounter in regenerative clinics.
What unites this list: every product has been through formal clinical trials, has a specific approved indication, and is manufactured under tightly regulated conditions. None of them are the same as the "stem cell injection" advertised on a billboard or in a local clinic.
03 · What is not approved
Most of what patients search for is not approved.
When patients type "stem cell therapy" into a search bar, they're usually looking for help with something the FDA has not approved any cellular product to treat. That includes:
- Bone marrow and adipose-derived autologous biologic procedures for orthopedic conditions (osteoarthritis, tendinopathy, ligament injury, avascular necrosis)
- IV or intranasal autologous biologic procedures for post-viral conditions (Long COVID), post-traumatic syndromes (TBI, suspected CTE), or other chronic systemic conditions
- Donor-derived "stem cell" injections marketed by some clinics, including umbilical cord blood, placental tissue, amniotic membrane, or expanded cell lines used outside approved indications
- "Stem cell" infusions advertised for general wellness, anti-aging, joint pain, neurodegenerative disease, autoimmune conditions, or any other off-label indication
Regulatory framing, Boulder Biologics
"No stem cell or cellular therapy is approved by the U.S. Food and Drug Administration (FDA) for the treatment of these conditions. The approaches described on this page are experimental, grounded in evolving translational and early clinical research, and offered only following comprehensive evaluation and informed consent."
What changes from clinic to clinic is whether the procedure is offered with that disclosure in front of the patient, or whether the clinic implies an approval that doesn't exist.
In 2019 and again at the end of the formal HCT/P enforcement-discretion period (which ran through May 31, 2021), the FDA stepped up enforcement against clinics marketing unapproved cellular products. Warning letters, permanent injunctions, and criminal referrals have all resulted.3,4 The clinics most often targeted were those selling donor-derived products, those making cure or regeneration claims, and clinics that processed patients' own fat into cell products (stromal vascular fraction), as in the US Stem Cell and California Stem Cell Treatment Center cases.
04 · The line that matters
Autologous vs. allogeneic.
The regulatory line that matters most for patients is autologous (your own) vs. allogeneic (donor-derived).
Regulatory framing, Boulder Biologics
"The FDA has raised particular concern regarding allogeneic (donor-derived) stem cell products, including umbilical cord, placental, and amniotic products, marketed outside of approved clinical trials. This distinction is important, as FDA enforcement actions have primarily targeted unapproved donor-derived products marketed without appropriate authorization."
Same-day, minimally manipulated, autologous biologic therapy is treated as a clinical procedure. Bone marrow aspirated from your iliac crest, processed in our on-site lab within a few hours, and returned to your own body the same day operates within the long-standing "same surgical procedure" exception of 21 CFR 1271.15(b).5 It is legal, regulated as a clinical procedure, and the framing most carefully aligned with current FDA guidance.
Donor-derived "stem cell" products (umbilical cord, placental, amniotic) almost always cross into FDA drug-product territory. Most do not have FDA approval for the indications they're being marketed for. The bulk of FDA enforcement actions in this space target precisely this category.
Why this matters for patients
If a clinic offers you "stem cells" from a donor (umbilical cord, placenta, or amnion), its regulatory position is very different from that of a clinic using your own bone marrow. The former carries enforcement risk and is, in most cases, marketing an unapproved drug. The latter operates within an established clinical-procedure framework.
05 · Where we fit
Where Boulder Biologics fits in this framework.
Boulder Biologics
"At Boulder Biologics, we use autologous stem cells only."
"Consistent with FDA guidance, we avoid unsupported claims regarding 'stem cell' replacement or regeneration."
We call a procedure investigational when the evidence for that use is still early. We call it a same-day clinical procedure only when the HCT/P rules allow it. In practice:
- We do not market FDA approval that doesn't exist.
- We do not use donor-derived products: no umbilical cord, placental tissue, amniotic membrane, or expanded cell lines.
- We do not claim disease modification, regeneration, or cure for the conditions we evaluate.
- Every patient who receives a procedure does so after a comprehensive informed-consent process that includes the regulatory status of their specific indication.
- For indications where the evidence base is preliminary (Long COVID, TBI, post-viral, systemic), we explicitly label the approach as investigational and explain what the literature does and does not currently support.
What we offer is a careful conversation based on the evidence: what the procedure is, what the research suggests, what it cannot do, and whether it makes sense for you, which we work out together. Dr. Glowney reviews every case personally before any procedure is offered.
06 · Read more
Where to go next.
- Our FDA Guidelines page covers the HCT/P framework, 21 CFR 1271, the same-surgical-procedure exception, and what minimal manipulation means in practice.
- The FDA's own patient-facing resource: Important Patient and Consumer Information About Regenerative Medicine Therapies.
- The FDA's list of approved cellular and gene therapy products, the canonical source for what is and is not FDA-approved.
- The International Society for Cell & Gene Therapy's patient resources on unproven cellular therapies.
07 · Common questions
Frequently asked.
Why do some clinics still call their procedures "FDA approved"? +
Some are misusing the term. An "FDA registered facility" is not the same as an "FDA-approved product," but the two phrases sound alike to most people. Others are confused about the distinction between procedure and drug. Some are actively misrepresenting. FDA approval is product-specific and indication-specific. If a clinic claims it without naming the specific approved product and the indication it was approved for, the claim is unsupported.
If it's not FDA-approved, is it legal? +
For autologous procedures that fall within the same-surgical-procedure exception of 21 CFR 1271.15(b), yes: they are legal medicine performed as clinical procedures, not as approved drugs. For donor-derived products marketed outside clinical trials, often no, and the FDA has obtained injunctions against clinics offering them.
Does "investigational" mean experimental? +
Yes. Investigational means the approach is still being studied. There is early scientific evidence for it, but the FDA has not reviewed it or approved it as a treatment for a specific condition. We tell you this before any procedure. The approach is offered only after individual evaluation and informed consent.
How can I tell if a clinic is operating compliantly? +
A few good signals: they tell you the procedure is not FDA-approved (rather than implying it is); they use autologous (your own) material rather than donor cells; they don't claim cure or disease modification; they have a clear regulatory disclosure page; the physician performs the procedure personally.
Red flags: claims of "FDA registered" or "FDA approved" without specifics; donor-derived products advertised for orthopedic or systemic conditions; before-and-after marketing; "regrow your cartilage" / "reverse aging" cure language.
Why is Boulder Biologics willing to perform something that's "not FDA-approved"? +
Because "not FDA-approved" doesn't mean "not legitimate medicine." Many established clinical procedures, joint injections, surgical techniques, autologous tissue handling, operate as procedures rather than as approved drug products. The HCT/P framework specifically allows same-day autologous biologic therapy as a clinical procedure. We work within that framework, with full disclosure of regulatory status, and we don't make claims the evidence doesn't support.
References
Sources cited.
- 21 CFR Part 1271, Human Cells, Tissues, and Cellular and Tissue-Based Products. Electronic Code of Federal Regulations.
- U.S. Food and Drug Administration. Approved Cellular and Gene Therapy Products. Center for Biologics Evaluation and Research.
- U.S. Food and Drug Administration. Statement by FDA Commissioner Scott Gottlieb, M.D., and Biologics Center Director Peter Marks, M.D., Ph.D. on FDA's continued efforts to stop stem cell clinics and manufacturers from marketing unapproved products that put patients at risk. April 3, 2019.
- U.S. Food and Drug Administration. Important Patient and Consumer Information About Regenerative Medicine Therapies.
- U.S. Food and Drug Administration. Same surgical procedure exception under 21 CFR 1271.15(b): questions and answers regarding the scope of the exception. Guidance for Industry, November 2017.
- U.S. Food and Drug Administration. Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products: Minimal Manipulation and Homologous Use, Guidance for Industry and FDA Staff. July 2020.
- Dominici M, Nichols K, Srivastava A, et al. Positioning a scientific community on unproven cellular therapies: the 2015 International Society for Cellular Therapy perspective. Cytotherapy. 2015;17(12):1663–1666.
Related patient explainers